The Globe and Mail

Go to the Globe and Mail homepage

Jump to main navigationJump to main content

Press release from Business Wire

XDx and LabCorp Enter Into Collaboration and License Agreement to Develop Lupus Flare Predictor Test

Wednesday, May 23, 2012

XDx and LabCorp Enter Into Collaboration and License Agreement to Develop Lupus Flare Predictor Test07:30 EDT Wednesday, May 23, 2012 BRISBANE, Calif. (Business Wire) -- XDx, Inc. announced today that it has entered into a collaboration and license agreement with Laboratory Corporation of America® Holdings (LabCorp) (NYSE: LH) whereby each party will collaborate in marker discovery, and LabCorp will develop and commercialize a diagnostic test to predict flares of systemic lupus erythematosus (SLE). The agreement combines XDx's autoimmune diagnostics research and discovery experience and SLE blood sample database with LabCorp's diagnostic development and commercialization resources. Financial terms of the agreement were not disclosed. SLE, also known as lupus, is a chronic autoimmune disease affecting over 1.5 million people in the U.S., according to the Lupus Foundation of America. Lupus disease flares are periods of increased disease activity. The major challenge for physicians managing patients with lupus is to treat this active phase without allowing the treatment itself to cause long-term damage. Treatment for active lupus differs, depending on the organ systems involved and disease severity. Current treatment often includes a combination of drugs. Pierre Cassigneul, XDx's President and Chief Executive Officer, commented, “Building upon our success in the immune-mediated diagnostic market with our first approved product, AlloMap® Molecular Expression Testing, XDx is dedicated to expanding its pipeline of high value diagnostic tests to other diseases that involve the activity of the immune system. In lupus, we have developed an extensive, proprietary database of lupus blood samples that we will use in collaboration with LabCorp to initiate its development of a biomarker for the flare test. We look forward to a fruitful relationship with this world-class partner.” “Lupus remains a critical area of unmet medical need, and new tests are needed to help clinicians anticipate when patients may need additional therapeutic interventions for the treatment of flares,” stated LabCorp's Chief Medical Officer, Dr. Mark Brecher. “This agreement with XDx advances our strategy of developing and introducing tests to provide personalized information that can be used to help physicians and their patients.” About XDx XDx, Inc., based in Brisbane, California, is a molecular diagnostics company focused on the discovery, development and commercialization of non-invasive tests for the monitoring of transplant rejection and autoimmune diseases. The company has developed AlloMap Molecular Expression Testing, an FDA-cleared test, which provides transplant physicians with a tool to aid in the determination of the probability of acute cellular rejection for post-cardiac transplant patient management. Some of the AlloMap technology developed and implemented by XDx in heart transplant patient management may be applicable to other conditions that involve transplant rejection and diseases that affect the immune system. XDx's non-invasive technology offers the potential to decrease healthcare costs and improve the quality of life for patients with a variety of life-threatening or life-altering immune-mediated diseases. For more information, please visit: MediaBurns McClellanJustin JacksonMichelle SzwarcbergTel: 212-213-0006jjackson@burnsmc.commszwarcberg@burnsmc.comorXDx, Inc.Matthew MeyerChief Business OfficerTel: